# Haemolysis detection in microRNA-seq from clinical plasma samples

- 3
- 4 Melanie D. Smith<sup>1,2\*</sup>, Shalem Y. Leemaqz<sup>1</sup>, Tanja Jankovic-Karasoulos<sup>1</sup>, Dale
- 5 McAninch<sup>2</sup>, Dylan McCullough<sup>1</sup>, James Breen<sup>3,4</sup>, Claire T. Roberts<sup>1,2</sup>, Katherine A.

6 Pillman<sup>5</sup>\*

- 7
- <sup>1</sup> Flinders Health and Medical Research Institute, Flinders University, Bedford Park, SA,
   9 Australia
- <sup>2</sup> Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia
- <sup>3</sup> Indigenous Genomics, Telethon Kids Institute, Adelaide, SA, Australia
- 12 <sup>4</sup> College of Health & Medicine, Australian National University, Canberra, ACT, Australia
- <sup>5</sup> Centre for Cancer Biology, University of South Australia/SA Pathology, Adelaide, SA,
- 14 Australia
- 15
- 16
- 17 \* Correspondence: <u>melanie.smith@flinders.edu.au</u>, <u>katherine.pillman@unisa.edu.au</u>
- 18
- 19
- 20

# 21 Abstract

22 The abundance of cell-free microRNA (miRNA) has been measured in many body 23 fluids, including blood plasma, which has been proposed as a source with novel, 24 minimally invasive biomarker potential for several diseases. Despite improvements in 25 quantification methods for plasma miRNAs, there is no consensus on optimal reference 26 miRNAs or to what extent haemolysis may affect plasma miRNA content. Here we 27 propose a new method for the detection of haemolysis in miRNA high-throughput 28 sequencing (HTS) data from libraries prepared using human plasma. To establish a 29 miRNA haemolysis signature in plasma we first identified differentially expressed 30 miRNAs between samples with known haemolysis status and selected miRNA with 31 statistically significant higher abundance in our haemolysed group. Given there may be 32 both technical and biological reasons for differential abundance of signature miRNA. 33 and to ensure the method developed here was relevant outside of our specific context, 34 that is women of reproductive age, we tested for significant differences between 35 pregnant and non-pregnant groups. Here we report a novel 20 miRNA signature (miR-36 106b-3p, miR-140-3p, miR-142-5p, miR-532-5p, miR-17-5p, miR-19b-3p, miR-30c-5p, 37 miR-324-5p, miR-192-5p, miR-660-5p, miR-186-5p, miR-425-5p, miR-25-3p, miR-363-38 3p, miR-183-5p, miR-451a, miR-182-5p, miR-191-5p, miR-194-5p, miR-20b-5p) that can be used to identify the presence of haemolysis, in silico, in high throughput miRNA 39 40 sequencing data. Given the potential for haemolysis contamination, we recommend that 41 assay for haemolysis detection become standard pre-analytical practice and provide 42 here a simple method for haemolysis detection.

## 43 Introduction

44 MicroRNAs represent a class of short, ~22 nt single stranded non-coding RNA 45 transcripts found in the cytoplasm of most cells that act directly as post transcriptional 46 regulators of gene expression (1,2) and also coordinate extensive indirect 47 transcriptional responses (3). In their canonical action, miRNAs mediate the expression 48 of specific messenger RNA (mRNA) targets by binding to the 3`-untranslated region 49 (UTR) of transcripts by either repressing translation or marking them for degradation (4). In the canonical miRNA pathway, target specificity requires exact nucleotide sequence complementarity between the miRNA 'seed' region (the first 2-7 bases at the 5` end of the mature miRNA transcript) and the 3`-UTR of the mRNA. Importantly, miRNAs demonstrate tissue, temporal and spatial expression specificity and are known regulators of development, with most mammalian mRNAs harbouring conserved targets of one or many miRNAs (1,2,5).

56

57 miRNA expression is both temporally and spatially tissue-specific, with transcripts 58 identified beyond the cells in which they were synthesised, in various body fluids 59 including urine, saliva and blood plasma (6). Circulating cell-free miRNAs identified in 60 plasma are packaged in micro vesicles such as exosomes (7,8) or bound to protein 61 complexes such as argonaute 2 (Ago2), nucleophosmin 1 (NPM 1) and high density 62 lipoprotein (HDL) (9–11), making them exceptionally stable (6). This stability, coupled 63 with their minimally invasive accessibility, has suggested circulating cell-free miRNAs as 64 an important resource for the identification of novel biomarkers.

65

66 Whilst much progress has been made in the search for novel miRNA biomarkers of 67 disease processes (12–14), outcomes of this research approach are often inconsistent 68 or even contradictory (6). There are many reasons for this, including variations in 69 enrichment, extraction and quantification methods, variation between individuals, lack of 70 consensus regarding optimal reference miRNA for normalisation and the difficulty in 71 guantifying both the amount and guality of RNA transcripts from blood plasma samples (15,16). An important but often overlooked factor is the potential for sample haemolysis 72 73 during blood collection or sample preparation which results in miRNA from lysed RBCs 74 being spilled into and retained within the plasma sample to be assayed (15).

75

The issue of haemolysis altering the miRNA content of plasma and the potential for confounding biomarker discovery has been reported previously (15,17,18). Using RTqPCR Kirschner and colleagues (15) showed that contamination of plasma samples with the miRNA content of RBCs changed the abundance of both miR-16 and miR-451a. This, in turn, altered the relative abundance of potential biomarkers for

mesothelioma and coronary artery disease including miR-92a and miR-15. Using the same technique, Pritchard *et al.* (18) demonstrated in plasma that 46 of the 79 circulating miRNA cancer biomarkers were highly expressed in more than one blood cell type, noting that the effects of sample specific blood cell counts and haemolysis can alter the miRNA biomarker levels in a single patient sample up to 50-fold. As a result, the authors emphasised caution in classifying blood cell associated miRNAs as biomarkers given the possible alternate interpretation.

88

89 Haemolysis is associated with either blood collection or RNA extraction and sample 90 preparation. Thus, despite differences between the quantification methods, high 91 throughput sequencing data used in our study is equally susceptible to the confounding effects of sample haemolysis on miRNA abundance levels in plasma is RT-qPCR. 92 93 There are currently two gold standard approaches in the assessment of haemolysis in 94 plasma: 1. Delta quantification cycle ( $\Delta$ Cq), where expression levels of a known blood 95 cell associated miRNA (miR-451a) and a control miRNA (miR-23a) are determined 96 based on the difference between the two raw Cq values and 2. Spectrophotometry, 97 where absorbance is measured at 414 nm with the use of a spectrophotometer. In the 98 case of  $\Delta$ Cq assessment, miR-451a is known to vary and miR-23a is known to be invariant in plasma affected by haemolysis (15,16). Using spectrophotometry, 99 100 haemolysis is quantified by assessing the presence of cell free haemoglobin by 101 measuring the absorbance at 414 nm, the absorbance maximum of free haemoglobin 102 (19,20). Both methods require access to sufficient amounts of the original plasma 103 sample and the laboratory equipment required to perform the assays. Free access to a 104 web-tool that can perform in silico assessment of RBC contamination in human plasma 105 would be of exceptional value to the research community.

106

Whilst it is well established that haemolysis frequently occurs during extraction or processing of blood samples, the assessment of RBC contamination is rarely mentioned in publications. It is even more rare that the results of any such testing are present in the metadata assigned to publicly available sequencing data. There is currently no publicly available tool for analysis of haemolysis without access to the physical plasma

specimen. Although the theory underlying identification of haemolysis in plasma is 112 113 relatively straight-forward, surprisingly, to our knowledge this has never before been 114 extrapolated into a data-only, in silico approach. The paucity of haemolysis information 115 in the context of publicly available datasets, combined with the lack of tools to identify 116 affected datasets after the fact, substantially limits the utility of this data resource and 117 reproducibility of research findings. Further, it increases the risk that results obtained 118 may unwittingly represent blood-cell based phenomena rather than signatures of the 119 pathology of interest.

120

121 In this study, we assessed miRNA abundance in HTS data from libraries prepared using 122 human plasma from pregnant and non-pregnant women of reproductive age. Using a set of samples with confirmed haemolysis ( $\Delta Cq$  (miR-23a-miR-451a)), we established a 123 124 set of 20 miRNAs differentially abundant between plasma from samples with and 125 without substantiated haemolysis. Using the expression values of these 20 miRNAs as 126 a 'signature' of haemolysis, we calculated the difference between the mean normalised 127 expression levels of these miRNAs compared to those of all other miRNAs (as a 128 'background' set). This produced a quantitative metric which represents the strength of 129 the evidence of haemolysis in an individual sample. When this metric is interpreted in 130 the context of other samples, it can be used to identify sample(s) that display substantial 131 evidence of haemolysis. The researcher may consider discarding these samples from 132 further analyses or using caution in their interpretation. We consulted the EMBL-EBI 133 Expression Atlas (ebi.ac.uk) to ensure all signature miRNAs are identified in multiple 134 human tissues (male and female) and have no known developmental stage association. 135 For ease of application, we have developed this method into a web based Shiny/R 136 application, DraculR (a tool that allows a user to upload and assess haemolysis in highthroughput plasma miRNA-seq data), for use by the research community (DraculR: A 137 138 web-based application for *in silico* haemolysis detection in high throughput small RNA 139 sequencing data).

# 140 Results

#### 141 High throughput sequencing

142 Illumina NextSeg 75 bp single-end read sequencing was performed on miRNA libraries 143 from 154 plasma samples taken from 24 non-pregnant and 130 pregnant women aged 144 16 to 46 years (Qiagen, Hilden, Germany). Prior to sequencing, RT-qPCR was used to 145 analyse  $\Delta Cq$  (miR-23a-miR-451a), where the ratio of miR-23a to miR-451a (or  $\Delta Cq$ 146  $(miR-23a-miR-451a) \ge 7)$  correlates with the degree of haemolysis. We identified 14 147 plasma samples with a  $\Delta$ Cg of 7 or above (Supplementary Table 1). An average of ~2.9 million reads were sequenced per sample (range ~0.25-18.6 million reads). Thirty-one 148 149 libraries with < 1 million reads were considered to be unreliable due to low sequencing 150 output and were removed from further analyses. There was no difference in the 151 proportion of haemolysed and non-haemolysed data in the exclusion of samples due to 152 low library size (Fisher's exact test P-value = 0.7). Sequence alignment was performed 153 using BWA (21) to the human genome (version GRCh38) and miRNA read counts were 154 generated by mapping to human miRBase v22 (22,23) identifying 1,133 mature 155 miRNAs.

156

To analyse the effects of haemolysis on miRNA expression data from next generation sequencing, we first determined the number of unique mature miRNAs identified in each of our samples and analysed the data relative to read depth. Using an analysis of variance (ANOVA) we identified a significant difference between the haemolysed and non-haemolysed samples (P<0.05), with haemolysis being frequently associated with fewer mature miRNA species detected at a given read depth (Figure 1).



Haemolysis( $\Delta$ Cq) = miR-23a-miR-451 < 7 = miR-23a-miR-451 ≥ 7

164

**Figure 1**. The number of mature miRNA species identified in an individual sample increases with read depth for both haemolysed and non-haemolysed samples. However, the number of mature miRNA species identified for a given read depth is significantly lower (ANOVA, P-value =  $1.68 \times 10^{-9}$ ) in samples affected by haemolysis (maroon) when compared to a nonhaemolysed sample (black) of equal read depth.

170 microRNA haemolysis signature set

171 To ensure that miRNAs identified here were representative of those found in a broad set 172 of plasma samples, we first filtered to discard miRNAs of low abundance. After filtering, 173 189 highly abundant miRNA remained. Differential expression analysis comparing 174 miRNA read counts identified 138 miRNAs with a higher abundance in haemolysed 175 compared to non-haemolysed samples (statistically significant differentially expressed 176 miRNA, false discovery rate (FDR) < 0.05, with a log<sub>2</sub> fold change (log<sub>2</sub>FC) > 0) 177 (Supplementary Figure 1; Supplementary Figure 2a & b). We further ranked the 178 differentially expressed miRNAs based on log<sub>2</sub>FC, FDR and abundance levels and 179 subset the list such that only miRNAs which had a  $log_2FC > 0.9$  and were in the top 60

percent of each of the FDR and abundance rank criteria remained. This resulted in a
 high confidence set of 20 miRNA indicative of a haemolysis signature (Table 1).

182

183 For in silico assay of haemolysis in our data, we further removed miRNAs associated 184 with pregnancy to avoid confounding miRNA associated with haemolysis with those 185 associated with pregnancy. Differential expression analysis of miRNA read counts from 186 pregnancy and non-pregnancy samples identified 127 miRNAs (FDR < 0.05) that were 187 significantly differentially expressed between the groups (Supplementary Figure 3a & b). 188 Strikingly, one of our first observations highlighted the importance of including 189 haemolysis analysis as an adjunct in our study: miR-451a, which is the sole haemolysis 190 signature miRNA used in the current  $\Delta Cq$  (miR-23a-miR-451a) gold standard method 191 for haemolysis detection was discovered to be highly correlated with pregnancy status, 192 indicating a strong confounding factor in pregnancy studies when haemolysis levels are 193 estimated using RT-gPCR alone. Accordingly, miR-451a was removed from calculations 194 hereafter along with 9 other miRNAs that were differentially expressed between the 195 pregnant and non-pregnant groups from the core set of haemolysis signature miRNA. 196 This resulted in 10 miRNAs remaining for evaluation of haemolysis levels.

**Table 1.** 20 miRNAs with a general-use plasma haemolysis signature set. To remove

199 confounding effects within our pregnancy-specific dataset, we identified a subset of 10 abundant 200 miRNA which are invariant with respect to pregnancy.

200

miRNA	Log₂FC	Average Expression (log <sub>2</sub> CPM)	Adjusted P-value	Pregnancy Assoc.
miR-106b-3p	1.589	8.731	8.61 x 10 <sup>-15</sup>	no
miR-140-3p	1.073	10.098	2.75 x 10 <sup>-13</sup>	no
miR-142-5p	0.962	10.651	4.96 x 10 <sup>-12</sup>	no
miR-532-5p	1.288	7.237	4.96 x 10 <sup>-12</sup>	no
miR-17-5p	0.952	7.892	7.84 x 10 <sup>-12</sup>	no
miR-19b-3p	1.128	8.696	1.93 x 10 <sup>-09</sup>	no
miR-30c-5p	0.95	7.325	2.48 x 10 <sup>-09</sup>	no
miR-324-5p	1.304	7.186	2.50 x 10 <sup>-09</sup>	no
miR-192-5p	0.941	8.944	1.37 x 10 <sup>-08</sup>	no
miR-660-5p	1.305	7.62	3.45 x 10 <sup>-10</sup>	no
miR-186-5p	1.228	8.052	2.75 x 10 <sup>-13</sup>	yes
miR-425-5p	1.282	11.246	4.96 x 10 <sup>-12</sup>	yes
miR-25-3p	1.212	12.939	1.26 x 10 <sup>-11</sup>	yes
miR-363-3p	1.237	7.882	4.52 x 10 <sup>-11</sup>	yes
miR-183-5p	1.55	9.382	9.34 x 10 <sup>-11</sup>	yes
miR-451a	1.372	13.002	3.65 x 10 <sup>-10</sup>	yes
miR-182-5p	1.341	10.585	2.48 x 10 <sup>-09</sup>	yes
miR-191-5p	0.929	11.79	4.68 x 10 <sup>-09</sup>	yes
miR-194-5p	0.937	7.679	1.85 x 10 <sup>-08</sup>	yes
miR-20b-5p	0.932	7.43	1.96 x 10 <sup>-08</sup>	yes

202

Incorporating concepts from previous RT-qPCR analyses of haemolysis, we established a new measure of the inclusion of RBC associated miRNA in human plasma. After establishing the 20-miRNA signature associated with RBC content inclusion, we determined the geometric mean of the distribution of miRNA read counts as an appropriate measure of abundance and summary statistic. Using this summary statistic, our method calculates a 'Haemolysis Metric', defined as the difference between the

209 geometric means of the normalised abundance levels of the haemolysis miRNA 210 signature set compared to that of all other miRNAs (the 'background' set). Note that in a 211 case-control study, to reduce the risk of confounding the Haemolysis Metric with 212 experimental variables, the signature set should be reduced to exclude any miRNA 213 known to be differentially expressed between groups. In this case, the geometric mean 214 of the reduced signature set will be calculated, as defined in (1).

- 215
- 216 Let
- 217  $Z_x$  be the miRNA Reduced signature set (log<sub>2</sub> CPM counts)
- and  $Z_y$  be the Background miRNA set (log<sub>2</sub> CPM counts)
- 219 where  $x = 1,2,3, ..., p_1$  with  $p_1$  = the number of miRNA in Reduced signature set
- and  $y = 1, 2, 3, ..., p_2$  where  $p_2$  = the number of miRNA in Background
- and i = 1, 2, 3, ..., n where n = the sample size after filtering
- 222

Haemolysis Metric<sub>i</sub> = 
$$\sqrt[p_1]{\prod_{x=1}^{p_1} Z_{x_i}} - \sqrt[p_2]{\prod_{y=1}^{p_2} Z_{y_i}}$$

223

224

225 226

227 Prior to establishing a threshold for the new Haemolysis Metric we measured the linear dependence between the new Haemolysis Metric and the  $\Delta$ Cq (miR-23a-miR-451a) 228 229 metric by performing a Pearson's correlation. Our results indicated a Pearson's 230 correlation coefficient of 0.64 (P < 0.0001). With confidence in the correlation, to 231 establish a threshold for the Haemolysis Metric, we compared the results of the  $\Delta Cq$ 232 (miR-23a-miR-451a) and summary statistic methods directly. Briefly, we compared the 233 Haemolysis Metric to the  $\Delta$ Cq (miR-23a-miR-451a) results for matched samples and 234 established a cut off criterion for inclusion into the Clear (no haemolysis detected) and 235 Caution (haemolysis detected) groups (Figure 2a). We chose a threshold of  $\geq$  1.9 for the 236 assignment of "Caution" to individual samples based on the minimum summary statistic 237 difference of samples assayed using the  $\Delta Cq$  (miR-23a-miR-451a) metric of  $\geq$  7 (Figure 238 2a) and the minimal overlap between the distribution of the Haemolysis Metric in 239 haemolysed compared to non-haemolysed samples (Figure 2b). Where a sample is

(1)

240 assigned "Caution", researchers are advised to consider removing the sample, or to 241 continue with caution. Given the correlation of the two metrics is imperfect and the 242 arbitrary nature of choosing any cut-off, samples with a Haemolysis Metric close to the 243 1.9 cut-off may be interrogated further prior to any decision to retain or remove. Of the 244 121 samples assayed, 25 samples met the criteria for Caution. Of these, 12 were 245 previously determined as haemolysed or borderline using the  $\Delta$ Cg (miR-23a-miR-451a) 246 assay. We found that all samples identified as  $\Delta Cq \ge 7$  (Figure 2a, scarlet) are above 247 the criteria for the Haemolysis Metric (Figure 2a, horizontal grey bar; threshold  $\geq$  1.9). 248 Further, we identified 13 samples with a Haemolysis Metric  $\geq$  1.9 not included in the 249  $\Delta$ Cq (miR-23a-miR-451a) criteria.



**Figure 2**: (a) A comparison of the derived Haemolysis Metric and the  $\Delta$ Cq measure of haemolysis shows a clear correlation. We identified 13 samples (named) that we suggest should be discarded or used with caution in further analysis. (b) Histogram of Haemolysis Metric values from the 121 samples in our experiment, coloured according to their  $\Delta$ Cq (miR-23a-miR-451a) classification indicate a minimum Haemolysis Metric of  $\geq$  1.9 for samples previously identified as haemolysed.

## 256 Discussion

Through an analysis of differential miRNA expression in samples whose haemolysis levels were known, we identified a novel 20 miRNA signature indicative of haemolysis. Given our hypothesis that plasma samples contaminated with RBC content would contain proportionally higher levels of many RBC-associated miRNA, not just miR-451a, we established a method using a group of background miRNAs as a reference. Accordingly, as a group, signature miRNAs (microRNAs which are abundant in red

263 blood cells) are shown to be more highly abundant in samples contaminated with RBCs. 264 The degree of this change can be used as a measure of RBC content contamination 265 and quantified by comparing the geometric means of the expressions of RBC signature 266 miRNAs to that of the background set of miRNAs. We further established that where a 267 comparison between conditions is considered, for example in a biomarker discovery 268 experiment, any miRNA known to be associated with the condition for which the 269 biomarker is proposed should be removed to prevent confounding between the 270 condition of interest and the quantification of RBC-associated miRNA inclusion.

271

272 Our experimental results demonstrate that it is possible to identify a haemolysis 273 signature in silico, avoiding the effort and expense of lab validation, and in situations 274 where blood plasma samples are exhausted, otherwise unavailable or cost-prohibitive 275 to assay using current gold standard approaches. Given the limited access to physical 276 samples associated with publicly available data, the Haemolysis Metric technique 277 introduced here, provides the basis for the development of a publicly available tool 278 (DraculR: A web-based application for *in silico* haemolysis detection in high throughput 279 small RNA sequencing data).

280

281 Among the haemolysis miRNA signature is miR-451a (previously named miR-451). 282 commonly associated with RBC contamination and used in the calculation of  $\Delta Cq$  (miR-283 23a-miR-451a). However, we removed miR-451a together with 9 other miRNAs from 284 our calculation of distribution difference due to changes in miRNA abundance 285 associated with pregnancy. During pregnancy total blood volume increases, varying 286 between 20% to 100% above pre-pregnancy levels. This change, however, is not 287 uniform across all blood components as plasma volume increases proportionally more 288 than the RBC mass (24). This is an important consideration and highlights the limitation 289 of the current gold standard approach that uses two miRNAs rather than a larger 290 signature set to calculate a measure of contamination. If, as in this example, the 291 abundance of either miRNA used to determine the  $\Delta Cq$  is also affected by the condition 292 or pathology under investigation, the issue is two-fold. Firstly, you may identify miR-293 451a as being differentially abundant in the pathology of interest and propose its use as

294 a biomarker only to find that it is confounded by haemolysis. Secondly, you may, using 295 the  $\Delta Cq$  calculation, classify samples as haemolysed when the change in miR-451a 296 abundance is more appropriately associated with the pathology of interest. By 297 establishing a larger signature set of miRNAs to detect haemolysis in small RNA 298 sequencing from human plasma we hope to provide a resource to the community. To 299 overcome issues identified in previous studies, the flexibility and redundancy included in 300 our metric buffer against the issue of confounding conditions of interest with the 301 measure of haemolysis.

302

303 We found limited overlap between the miRNAs identified as useful for the detection of 304 haemolysis and those previously reported as markers of haemolysis contamination (15,18,25). When comparing with previous research, it is important to note, that our 305 306 research question differed from that of the above studies, as did our study methodology. 307 The most important technical difference is in the quantification of miRNAs. The 308 expression values used here were taken from a HTS experiment, rather than RT-qPCR 309 used previously. The limitations of RT-qPCR to investigate which miRNAs are affected 310 by haemolysis has been identified previously (26). Given that HTS allows for 311 quantification of all known miRNA species and that RT-qPCR is targeted, our 312 experiment was able to identify differential abundance in miRNAs not quantified in 313 Kirschner et al. (15), Pritchard et al. (18) or McDonald et al. (25). Whilst we identified an 314 overlap in the miRNAs associated with haemolysis in this and previous work, many of 315 these were not included in the final miRNA Haemolysis Metric signature set. These 316 include miR-16, miR-486-5p and miR-92a-3p which were significantly upregulated in the 317 haemolysed group, but not included in the signature set as they failed to pass filtering criteria for log<sub>2</sub>FC and expression level. Secondary to the technical differences 318 319 introduced by using different miRNA quantification technologies, it is important to note 320 that all plasma samples used here to establish which miRNAs are affected by 321 haemolysis were taken from adult women of reproductive age. No sex or age 322 information was included with either of the compared studies, although it is likely these 323 samples included specimens from men and women. To account for the potential bias 324 introduced using data from only female and all reproductively aged volunteers, we

ensured all miRNAs included here have previously been identified in multiple tissues in
both male and female samples and are not affected by developmental stage.
Investigation using a cohort of mixed age and sex is warranted and may help to further
determine which miRNAs are affected by haemolysis.

329

330 Interestingly, all signature miRNAs, with the exception of miR-325-5p, have previously 331 been reported as prognostically valuable plasma or serum biomarkers. In this small 332 sampling of recent miRNA biomarker research, we identified several instances where 333 more than one of our haemolysis signature miRNA were identified as disease 334 biomarkers for the same condition in the same experiment (27–29) which, given our 335 findings, and those of previous haemolysis research, further call into question their validity as biomarkers of disease or condition. In conjunction with our research, we 336 337 found many miRNAs as suggested circulating biomarkers for multiple disease states. 338 For example, miR-122 was given biomarker potential in liver disease, lung cancer and 339 myasthenia gravis (14,27,30), and miR-660 was given biomarker potential in 340 Alzheimer's disease, breast cancer and lung cancer (28,31,32), respectively. These 341 miRNAs may represent effective biomarkers, but they may simply highlight RBC 342 contamination or be indicative of a general state of inflammation.

343

344 Data contained in this study were obtained from two cohorts of female volunteers of 345 reproductive age. Whilst we are working in a relatively narrow experimental domain, we 346 have generalised this method such that removal (from the signature miRNA set) of 347 domain specific miRNA is built in, providing a framework that allows use within research 348 conducted in any human plasma context. Our results highlight that ignoring the issue of 349 miRNA from RBCs leaves researchers open to the risk that newly discovered miRNA 350 disease biomarkers could in fact be biomarkers of haemolysis. In future research, a 351 repeat experiment with samples taken from male and female individuals across a wider 352 age range would expand and strengthen our understanding of the impact of haemolysis 353 on biomarker discovery. Our research both recommends and enables tests for 354 haemolysis to become standard pre-analytical practice.

# 355 Methods

#### 356 Sample collection

357 Peripheral blood (9 mL) was collected with informed, written consent from women 358 undergoing elective terminations of otherwise healthy pregnancies. Blood was collected 359 into standard EDTA blood tubes pre-termination and stored on ice until processed. 360 Whole blood underwent centrifugation at 800 x g for 15 minutes at 4°C before plasma 361 removal and then spun for a further 15 minutes to ensure any remaining cellular debris, 362 including cell membranes from lysed red blood cells, was removed. All samples were 363 stored at -80°C until further processing. Termination samples were collected from the 364 Pregnancy Advisory Centre (PAC), Woodville, South Australia. Blood was also collected 365 with informed, written consent from non-pregnant volunteers at the Adelaide Medical 366 School. Following collection, blood tubes were stored on ice until processing. Whole 367 blood underwent centrifugation at 1015 x g for 10 minutes at 4°C. Approximately 4-6 mL 368 plasma was collected in 2 mL aliquots. 500 µL plasma (the supernatant) were aliquoted 369 into clean tubes and the pellet containing any remaining blood cells at the bottom of the 370 tube was discarded. All samples were stored at -80°C until further processing.

#### 371 RNA extraction and library preparation

MicroRNA was isolated from 200 µL plasma samples using the QIAGEN miRNA
 serum/plasma kit (Qiagen, Hilden, Germany) according to the manufacturer's
 instructions and stored at -80°C.

Library preparation and sequencing was performed by Qiagen (Valencia, CA) using the QIAseq miRNA Library Kit and QIAseq miRNA 48 Index IL kits as per manufacturer's instructions. Amplified cDNA libraries underwent single-end sequencing by synthesis (Illumina v1.9).

#### 379 Haemolysis Detection by RT-qPCR

380 Plasma samples were examined for haemolysis based on the expression levels of two 381 miRNAs: miR-451a and miR-23a. miR-451a (previously named miR-451) is known to be 382 highly expressed in red blood cells, whereas miR-23a is known to maintain stable 383 abundance levels in plasma. After RNA extraction and cDNA synthesis, the delta 384 quantification cycle (Cq) values for miR-23a-miR-451a were calculated independently 385 for each sample. The evaluation of expression levels was performed based on raw Cq 386 values. According to the Qiagen protocol for haemolysis detection (Qiagen, Hilden, 387 Germany) using the  $\Delta\Delta$ Cg method, samples with a  $\Delta$ Cg <7 for these two miRNAs were 388 considered as clear of contamination; a  $\Delta Cq > 7$  was considered contaminated; a  $\Delta Cq$ 389 =7 was considered borderline.

#### 390 miRNA annotation and abundance

391 Read quality metrics (33)control were assessed using FastQC 392 (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) to check for per base 393 sequence quality, sequence length distribution and duplication levels. Adapter detection 394 and trimming were performed using Atropos (34). Alignment performed using BWA 395 version 0.7.17-r1188 (GRCh38) (21). Umi\_tools was used to collapse duplicate reads 396 mapped to the same genomic location with the same UMI barcode. Quality control 397 metrics were reported using multiQC (35). Read counts for mature miRNAs were determined using an in-house script (36) with microRNA annotation from miRBase, 398 399 version 22.0 (22,23) (http://www.mirbase.org).

### 400 Analysis of potential confounding factors

All profile and expression analyses were conducted in the R statistical environment (v.4.0.2), using the *edgeR* (v.3.16.5) (37) and *limma* (v.3.30.11) (38) R/Bioconductor packages. Prior to conducting the differential expression analysis between haemolysed and non-haemolysed expression data we considered the effect of participant characteristics such as sex, age, smoking, pregnancy status and ethnicity. Sex was not 406 included here as all samples were taken from female participants. Maternal age was 407 excluded from the final regression model as there was no strong evidence of 408 association with the outcome and hence considering the sample size a simpler model 409 was chosen to preserve degrees of freedom. miRNA identified as differentially 410 expressed between samples from pregnant and non-pregnant women, were removed 411 from the final set of haemolysis signature miRNA. Sequencing batch was also included 412 in all regression models.

#### 413 Identification of haemolysis miRNA signature

414 Prior to defining a collection of haemolysis informative miRNAs, pre-filtering steps were 415 undertaken: 1) mature miRNA with fewer than five reads were reduced to zero 416 independently for each sample, 2) miRNA with fewer than 40 counts per million (CPM) 417 in the haemolysed group (n = 12) were removed from further consideration. This was 418 done to ensure only highly abundant miRNA likely to be present in most samples 419 remain. The Trimmed Means of M values (TMM) normalisation method was used to 420 correct for differences in the underlying distribution of miRNA expression (39). Next, we 421 used limma (38) to obtain the fold change of each miRNA between the haemolysed and 422 non-haemolysed groups to identify miRNAs that are more abundant in the plasma 423 affected by haemolysis. To ensure the haemolysis miRNA signature was robust, we 424 took the intersection of the 60 miRNAs from each category of highest expression and 425 lowest adjusted P-value and miRNAs with a  $\log_2 FC > 0.9$ , revealing a set of twenty high 426 confidence miRNAs. To further refine the set of haemolysis informative miRNAs we 427 used *limma* to calculate the fold change for each miRNA between the samples from 428 pregnant and non-pregnant women not affected by haemolysis and removed any of the 429 high-confidence miRNA which was also differentially abundant in pregnancy. The 430 workflow, source code and input files associated with this research are available at 431 (https://github.com/mxhp75/haemolysis maternaPlasma.git).

#### 432 Classification - Haemolysis Metric

To classify the data coming from samples as haemolysed, borderline or unaffected we first focused on samples from the non-pregnant group. For these, we subset the miRNA read count table into miRNA from the high confidence haemolysis informative miRNA (n=20) and all others (n=169). Using this data partition we calculated the geometric mean of the distribution of read counts using the *psych* package (v1.8.12) (40) and subtracted the geometric mean of the counts of "other" miRNA from that of the "haemolysis informative" miRNA. Next, for samples from the pregnant group, we performed the same calculations described above after first discarding miRNA which were associated with pregnancy.

# 442 Ethics

Ethics approval for the collection of blood from women undergoing elective pregnancy
termination between 6–23 weeks' gestation was provided under HREC/16/TQEH/33, by
The Queen Elizabeth Hospital Human Research Ethics Committee (TQEH/LMH/MH).
Blood from women forming the general population group was collected after informed
consent with ethics approval provided under HREC/H/021/2005, by The University of
Adelaide Human Research Ethics Committee.

# 449 Author contribution

450 CTR created the concept and acquired funding. MS, KP and JB conceived and 451 developed experimental plans. TJK, DMcA and DMcC performed experiments. MS and 452 KP analysed the sequencing data with statistical support from SYL. Manuscript written 453 by MS and KP. All authors read and approved the final version of the manuscript.

# 454 Funding information

455

This research is supported by NIH NICHD R01 [grant number HD089685-01] Maternal
molecular profiles reflect placental function and development across gestation PI
Roberts. MDS was supported by an Australian Government Research Training Program
(RTP) Scholarship. CTR is supported by a National Health and Medical Research
Council Investigator Grant [grant number GNT1174971] and a Matthew Flinders
Professorial Fellowship funded by Flinders University. JB is supported by the James &

462 Diana Ramsay Foundation. KAP is supported by the Florey Fellowship funded by the463 Adelaide Hospital Research Committee.

464

# 465 Acknowledgements

We wish to acknowledge the generosity of the women who donated their blood for our
research. Without them, this research would not be possible. We also acknowledge
valuable input from QIAGEN Genomic Services.

# 470 Supplementary Information Legends

471

**Supplementary figure 1**: Haemolysis signature feature selection. Raw single-end reads from small RNA-seq libraries are pre-processed using a range of Unix- and python-based computational tools to quantify miRNA expression in each library. Data quality is ensured through quality control steps throughout the workflow. Concurrently with sequencing,  $\Delta$ Cq (miR-23a-miR-451) was assessed by RT-qPCR and incorporated into the differential expression analysis.

478

**Supplementary Figure 2**: (a) Volcano plot of differential expression. Linear regression identified 138 miRNA which were more highly abundant in haemolysed compared to non-haemolysed samples with FDR < 0.05 (green). (b) MA plot (M (log ratio) and A (mean average)) of Log2 fold change as a function of Log2 average expression indicates most miRNA have an average expression < 10 Log2 CPM. miR-451a and miR-16-5p, both highly red blood cell associated, are highly expressed and more abundant in the haemolysed group (green).

486

487 Supplementary Figure 3: (a) Volcano plot of differential expression between the 488 pregnant and non-pregnant samples. Linear regression identified 104 miRNA (FDR < 489 0.05) which were more highly abundant in the pregnant population (red). Haemolysis 490 Metric signature miRNAs are labelled (b) MA plot (M (log ratio) and A (mean average)) of 491 Log<sub>2</sub> fold change as a function of Log<sub>2</sub> average expression indicates most miRNA have 492 an average expression  $< 10 \text{ Log}_2 \text{ CPM}$ . Unsurprisingly, the most differentially expressed 493 miRNA are miR-517a-3p, miR-517b-3p, miR-516b-5p, miR-518b, which are all 494 members of the highly placenta associated chromosome 19 miRNA cluster.

495

496 **Supplementary Table 1**: RT-qPCR Cq data for miR-23a-3p, miR-451a and  $\Delta$ Cq (miR-497 23a-miR-451).

# 499 Reference

- Bartel DP. MicroRNAs: Genomics, Biogenesis, Mechanism, and Function [Internet].
   Vol. 116, Cell. 2004. p. 281–97. Available from:
- 503 http://linkinghub.elsevier.com/retrieve/pii/S0092867404000455
- 504 2. Bartel DP. Metazoan MicroRNAs. Cell. 2018 Mar 22;173(1):20–51.
- Pillman KA, Scheer KG, Hackett-Jones E. Extensive transcriptional responses are co-ordinated by microRNAs as revealed by Exon–Intron Split Analysis (EISA).
   Nucleic acids [Internet]. 2019; Available from: https://academic.oup.com/nar/articleabstract/47/16/8606/5542881
- 509 4. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs
  510 predominantly act to decrease target mRNA levels. Nature. 2010 Aug
  511 12;466(7308):835–40.
- 5. Friedman RC, Farh KK-H, Burge CB, Bartel DP. Most mammalian mRNAs are 513 conserved targets of microRNAs. Genome Res. 2008 Oct 29;19(1):92–105.
- Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL,
   et al. Circulating microRNAs as stable blood-based markers for cancer detection.
   Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513–8.
- 517 7. Cortez MA, Calin GA. MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther. 2009 Jun;9(6):703–11.
- 8. Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential
  biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010
  Oct;101(10):2087–92.
- Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011 Apr;13(4):423–33.
- Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, et al.
   Argonaute2 complexes carry a population of circulating microRNAs independent of
   vesicles in human plasma. Proceedings of the National Academy of Sciences. 2011
   Mar 22;108(12):5003–8.
- 529 11. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA.
   530 MicroRNAs in body fluids—the mix of hormones and biomarkers. Nat Rev Clin
   531 Oncol. 2011 Aug 1;8(8):467–77.
- Ali SA, Gandhi R, Potla P, Keshavarzi S, Espin-Garcia O, Shestopaloff K, et al.
   Sequencing identifies a distinct signature of circulating microRNAs in early

- radiographic knee osteoarthritis. Osteoarthritis Cartilage. 2020 Nov;28(11):1471–
  81.
- 536 13. Witwer KW. Circulating microRNA biomarker studies: pitfalls and potential
   537 solutions. Clin Chem. 2015 Jan;61(1):56–63.
- 538 14. Wozniak MB, Scelo G, Muller DC, Mukeria A, Zaridze D, Brennan P. Circulating
   539 MicroRNAs as Non-Invasive Biomarkers for Early Detection of Non-Small-Cell Lung
   540 Cancer. PLoS One. 2015 May 12;10(5):e0125026.
- 541 15. Kirschner MB, Kao SC, Edelman JJ, Armstrong NJ, Vallely MP, van Zandwijk N, et
  542 al. Haemolysis during sample preparation alters microRNA content of plasma.
  543 Pfeffer S, editor. PLoS One. 2011 Sep 1;6(9):e24145.
- 544 16. Cheng HH, Yi HS, Kim Y, Kroh EM, Chien JW, Eaton KD, et al. Plasma Processing
  545 Conditions Substantially Influence Circulating microRNA Biomarker Levels. Kiechl
  546 S, editor. PLoS One. 2013 Jun 7;8(6):e64795.
- 547 17. Kirschner MB, van Zandwijk N, Reid G. Cell-free microRNAs: potential biomarkers
   548 in need of standardized reporting. Front Genet. 2013 Apr 19;4:56.
- 549 18. Pritchard CC, Kroh E, Wood B, Arroyo JD, Dougherty KJ, Miyaji MM, et al. Blood
  550 cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies.
  551 Cancer Prev Res . 2012 Mar;5(3):492–7.
- Livak KJ, Schmittgen TD. Analysis of Relative Gene Expression Data Using Real Time Quantitative PCR and the 2–ΔΔCT Method [Internet]. Vol. 25, Methods. 2001.
   p. 402–8. Available from: http://dx.doi.org/10.1006/meth.2001.1262
- Wong C-H, Song C, Heng K-S, Kee IHC, Tien S-L, Kumarasinghe P, et al. Plasma
   free hemoglobin: a novel diagnostic test for assessment of the depth of burn injury.
   Plast Reconstr Surg. 2006 Apr;117(4):1206–13.
- 558 21. Li H, Durbin R. Fast and accurate long-read alignment with Burrows–Wheeler 559 transform. Bioinformatics. 2010 Jan 15;26(5):589–95.
- 560 22. Griffiths-Jones S. miRBase: microRNA sequences and annotation. Curr Protoc
   561 Bioinformatics. 2010 Mar;Chapter 12:Unit 12.9.1-10.
- 562 23. Kozomara A, Griffiths-Jones S. MiRBase: Annotating high confidence microRNAs
  563 using deep sequencing data. Nucleic Acids Res [Internet]. 2014;42(D1). Available
  564 from: http://dx.doi.org/10.1093/nar/gkt1181
- 565 24. Sanghavi M, Rutherford JD. Cardiovascular physiology of pregnancy. Circulation.
   566 2014 Sep 16;130(12):1003–8.

- 567 25. McDonald JS, Milosevic D, Reddi HV, Grebe SK, Algeciras-Schimnich A. Analysis
   568 of circulating microRNA: preanalytical and analytical challenges. Clin Chem. 2011
   569 Jun;57(6):833–40.
- 570 26. Kirschner MB, Edelman JJB, Kao SCH, Vallely MP, Van Zandwijk N, Reid G. The
   571 impact of hemolysis on cell-free microRNA biomarkers. Front Genet.
   572 2013;4(MAY):94.
- 573 27. Nogales-Gadea G, Ramos-Fransi A, Suárez-Calvet X, Navas M, Rojas-García R,
  574 Mosquera JL, et al. Analysis of serum miRNA profiles of myasthenia gravis
  575 patients. PLoS One. 2014 Mar 17;9(3):e91927.
- 576 28. Guo R, Fan G, Zhang J, Wu C, Du Y, Ye H, et al. A 9-microRNA Signature in
  577 Serum Serves as a Noninvasive Biomarker in Early Diagnosis of Alzheimer's
  578 Disease. J Alzheimers Dis. 2017;60(4):1365–77.
- Poroyko V, Mirzapoiazova T, Nam A, Mambetsariev I, Mambetsariev B, Wu X, et
  al. Exosomal miRNAs species in the blood of small cell and non-small cell lung
  cancer patients. Oncotarget. 2018 Apr 13;9(28):19793–806.
- 30. Wang X, He Y, Mackowiak B, Gao B. MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases. Gut. 2021 Apr;70(4):784–95.
- 31. Zou X, Li M, Huang Z, Zhou X, Liu Q, Xia T, et al. Circulating miR-532-502 cluster
  derived from chromosome X as biomarkers for diagnosis of breast cancer. Gene.
  2020 Jan 5;722:144104.
- 32. Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F, et al. MicroRNA
  signatures in tissues and plasma predict development and prognosis of computed
  tomography detected lung cancer. Proc Natl Acad Sci U S A. 2011 Mar
  1;108(9):3713–8.
- 33. Andrews S. FastQC: a quality control tool for high throughput sequence data
  [Internet]. 2010. Available from:
  http://www.bioinformatics.babraham.ac.uk/projects/fastqc/
- 594 34. Didion JP, Martin M, Collins FS. Atropos: specific, sensitive, and speedy trimming 595 of sequencing reads. PeerJ. 2017 Aug 30;5:e3720.
- 596 35. Ewels P, Magnusson M, Lundin S, Käller M. MultiQC: Summarize analysis results
  597 for multiple tools and samples in a single report. Bioinformatics. 2016;32(19):3047–
  598 8.
- 36. Saunders K, Bert AG, Dredge BK, Toubia J, Gregory PA, Pillman KA, et al.
  Insufficiently complex unique-molecular identifiers (UMIs) distort small RNA
  sequencing. Sci Rep. 2020 Sep 3;10(1):14593.

- 37. Robinson MD, McCarthy DJ, Smyth GK. edgeR: A Bioconductor package for
   differential expression analysis of digital gene expression data. Bioinformatics.
   2009;26(1):139–40.
- 38. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers
  differential expression analyses for RNA-sequencing and microarray studies.
  Nucleic Acids Res. 2015;43(7):e47.
- 39. Robinson MD, Oshlack A. A scaling normalization method for differential
   expression analysis of RNA-seq data. Genome Biol. 2010 Mar 2;11(3):R25.
- 40. Revelle W. psych: Procedures for Psychological, Psychometric, and Personality
   Research [Internet]. Evanston, Illinois: Northwestern University; 2021. Available
   from: https://CRAN.R-project.org/package=psych